Recombinant human interferon α2b for injection

Pharmacology: Recombinant human interferon α2b has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement. Interferon binds to cell surface receptors to induce cells to produce a variety of antiviral proteins, inhibit virus reproduction in cells, and improve immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: The product was injected intraperitoneally and intravenously into mice at doses of 1.5×109IU/kg and 1.5×108IU/kg, respectively, which are 105 and 104 times the therapeutic dose for humans. No acute poisoning symptoms occurred, and no animals died. Long-term toxicity test: The product was injected intramuscularly into rats at doses of 1.5×107IU/kg, 1.5×106IU/kg and 1.5×105IU/kg, 5 times a week for 6 months. There were no abnormalities in the general condition, weight and behavior of the rats. The above test was repeated in rabbits, and no toxic reactions were observed during three months. Pathological tissue examination of the rabbits' internal organs revealed no changes caused by the toxicity of this product.

Recombinant human interferon alpha;1b.

This product is a white, thin, loose shell. After adding 1 ml of distilled water, it dissolves into a clear liquid and contains no insoluble matter visible to the naked eye.

This product is suitable for the treatment of viral diseases and certain malignant tumors. It has been approved for the treatment of chronic hepatitis B, hepatitis C and hairy cell leukemia. Clinical trial results and literature reports have shown that it is effective in treating viral diseases such as herpes zoster, condyloma acuminatum, epidemic hemorrhagic fever and respiratory syncytial virus pneumonia in children. It can be used to treat malignant tumors such as chronic myeloid leukemia, melanoma, lymphoma, etc.

Dissolve each vial with 1 ml of sterile water for injection and inject intramuscularly or subcutaneously. The dosage and course of treatment are as follows: Chronic hepatitis B: 30~60g of this product once, once every other day, subcutaneously or intramuscularly, for a course of 4~6 months, which can be extended to 1 year depending on the condition. Induction therapy can be performed, that is, at the beginning of treatment, take the drug once a day, and change it to once every other day after 0.5~1 month until the end of the course of treatment. Chronic hepatitis C: 30~60g of this product once, once every other day, subcutaneously or intramuscularly. Treat for 4~6 months, and stop if ineffective. Those who are effective can continue treatment for up to 12 months. It can be extended to 18 months depending on the condition. In the first month of treatment, take it once a day. Follow up for 6~12 months after the end of the course of treatment. Acute hepatitis C should be treated with this product early to reduce chronicity. Chronic myeloid leukemia: 30~60g of this product once a day, subcutaneously or intramuscularly, and continue to use it for more than 6 months. It can be adjusted appropriately according to the condition, and can be changed to injection every other day after remission. Hairy cell leukemia: 30~60g of this product once, once a day, subcutaneous or intramuscular injection, continuous medication for more than 6 months. It can be adjusted according to the condition of the disease. Genital warts: 10~30g of this product once, subcutaneous or intramuscular injection, or 10g once, local injection under the wart, once every other day, 3 consecutive weeks as a course of treatment. The course of treatment can be extended or repeated according to the condition. Tumor: 30~60g of this product once, once a day or once every other day, continuous medication for more than 6 months. The course of treatment can be extended depending on the condition. If the patient does not experience rapid deterioration of the condition or serious adverse reactions, the medication should be continued at an appropriate dose.

The adverse reactions of this product are mild, the most common of which are fever, fatigue, etc., which often appear in the early stage of medication and are mostly one-time and reversible reactions; other possible adverse reactions include headache, myalgia, joint pain, loss of appetite, nausea, etc.; a few patients may experience abnormal blood counts such as leukopenia and thrombocytopenia, which can be restored after stopping the drug. If there are serious adverse reactions that the patient cannot tolerate, the dosage should be reduced or the drug should be stopped, and necessary symptomatic treatment should be given.

1. People who are known to be allergic to interferon products. 2. People with a history of angina pectoris, myocardial infarction, or other serious cardiovascular diseases. 3. People with other serious diseases who cannot tolerate the side effects of this product. 4. People with epilepsy and other central nervous system disorders.

Sleeping pills and sedatives should be used with caution when using this product.

Store at 2-8℃ away from light.

3 million IU/vial

Anhui Anke Biotechnology (Group) Co., Ltd.

• Founded in:

  2000-09-28

• Address:

  K-1, Customs Road, High-tech Zone, No. 669, Changjiang West Road, Hefei, Anhui Province

• Tax NO.:

  91340100149030777L

• Registered Funds:

  1,672,553,658 yuan

• Website:

  Log in to view

• Email:

  Log in to view